Literature DB >> 9862169

Metabolic modes of action of the statins in the hyperlipoproteinemias.

C A Aguilar-Salinas1, H Barrett, G Schonfeld.   

Abstract

Conflicting results have been published during the past few years regarding the physiologic modes of action of the hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors, generally referred to as statins, using standard doses. Three mechanisms have been described: increased LDL catabolic rate, increased removal of LDL precursors resulting in decreased LDL production and decreased VLDL production. The physiologic effects of statins seem to depend on the underlying pathology of the disorders under therapy. More recent data using either the more potent atorvastatin or larger doses of previously available statins (e.g. simvastatin 80-160 mg/day), suggest that both the potency of the statins and the underlying pathopHysiology are important in determining the predominant physiologic responses of patients. To understand physiologic responses more completely, drug-dose-physiologic response curves of apo B kinetics in various groups of patients are needed. Simultaneous studies of apo B, triglycerides and cholesterol metabolism are also needed and are currently feasible.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862169     DOI: 10.1016/s0021-9150(98)00198-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin.

Authors:  Raul D Santos; Ana P M Chacra; Aleksandra Morikawa; Carmen C Vinagre; Raul C Maranhão
Journal:  Lipids       Date:  2005-07       Impact factor: 1.880

2.  Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.

Authors:  Paul D Martin; Patrick D Mitchell; Dennis W Schneck
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

3.  Postoperative Cardiac Surgery Outcomes in a Statin-Native Population.

Authors:  Sameh Aboulnaga; Ahmed Mahfouz; Hesham A Ewila; Alejandro Kohn Tuli; Rajvir Singh; Amr S Omar; Abdulaziz Al Khualifi
Journal:  Anesth Essays Res       Date:  2018 Jan-Mar

4.  Simvastatin Downregulates Cofilin and Stathmin to Inhibit Skeletal Muscle Cells Migration.

Authors:  Li-Ping Lin; Tung-Yang Yu; Hsiang-Ning Chang; Wen-Chung Tsai; Jong-Hwei S Pang
Journal:  Int J Mol Sci       Date:  2022-03-05       Impact factor: 5.923

5.  Simvastatin induces apoptosis of fibroblast-like synoviocytes.

Authors:  Ira Litinsky; Itshak Golan; Michael Yaron; Ilana Yaron; Dan Caspi; Ori Elkayam
Journal:  Open Rheumatol J       Date:  2009-09-07

6.  Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study).

Authors:  Carlos A Aguilar-Salinas; Andréia Assis-Luores-Vale; Benjamín Stockins; Hector Mario Rengifo; José Dondici Filho; Abrahão Afiune Neto; Lísia Marcílio Rabelo; Kerginaldo Paulo Torres; José Egídio Paulo de Oliveira; Carlos Alberto Machado; Eliana Reyes; Victor Saavedra; Fernando Florenzano; Ma Victoria Hernández; Sergio Hernandez Jiménez; Erika Ramírez; Cuauhtémoc Vazquez; Saul Salinas; Ismael Hernández; Octavio Medel; Ricardo Moreno; Paula Lugo; Ricardo Alvarado; Roopa Mehta; Victor Gutierrez; Francisco J Gómez Pérez
Journal:  Cardiovasc Diabetol       Date:  2004-07-23       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.